摘要
目的:了解阿德福韦酯(ADV)联合干扰素α-2b(IFN-α2b)治疗慢性乙型肝炎(CHB)的安全性及疗效。方法:选择33例慢性乙型肝炎患者(联合治疗组),采用ADV和IFN-α2b联合治疗方案;30例慢性乙型肝炎患者(对照组)单用ADV治疗,疗程为12个月。结果:联合治疗组治疗CHB安全性和耐受性良好,HBV-DNA转阴率和HBeAg/抗HBe血清转换率较对照组均有明显提高,差异有统计学意义。结论:阿德福韦酯联合干扰素α-2b抗乙肝病毒优于单一用药。
Objective：To realize the safety and efficacy of adefovirdipivoxil（ADV） and interferon α-2b（IFN-α2b） for chronic hepatitis B（CHB） patients.Methods：Selected 33 patients with chronic hepatitis B patients（combination therapy group） who were adopted by ADV and IFN-α-2b combination therapy.30 patients with chronic hepatitis B patients（control group） were treated by ADV.All patients were treated for 12 months.Results：The CHB safety and tolerance charecteristic of combined treatment group were satisfied,HBV DNA negative conversion rate and HbeAg/anti Hbe seroconversion rates were significantly improved compared with the control group（P0.05）.Conclusion：Adefovir dipivoxil combined interferon α-2b for anti-hepatitis B virus is superior than monotherapy.
出处
《中国当代医药》
2010年第36期35-36,共2页
China Modern Medicine
